Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway
Clinical Science · 2024
DOI: 10.1042/cs20240302 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2024. Verfasst von Roberto Palacios-Ramirez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Université, Inserm, Université de Paris, Paris, Fra…. Hauptthemen laut MEDLINE: Mineralocorticoid Receptor Antagonists, Toll-Like Receptor 4, Eplerenone, Receptors, Mineralocorticoid. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 2.0). Gefördert von: Agence Nationale de la Recherche (ANR), Institut National de la Santé et de la Recherche Médicale (Inserm).
Abstract (Originalsprache)
Excessive activation of the mineralocorticoid receptor (MR) is implicated in cardiovascular and renal disease. Decreasing MR activation with MR antagonists (MRA) is effective to slow chronic kidney disease (CKD) progression and its cardiovascular comorbidities in animal models and patients. The present study evaluates the effects of the MR modulator balcinrenone and the MRA eplerenone on kidney damage in a metabolic CKD mouse model combining nephron reduction and a 60% high-fat diet. Balcinrenone and eplerenone prevented the progression of renal damages, extracellular matrix remodeling and inflammation to a similar extent. We identified a novel mechanism linking MR activation to the renal proteoglycan deposition and inflammation via the TLR4 pathway activation. Balcinrenone and eplerenone similarly blunted this pathway activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche des Cordeliers, Team Diabetes, Metabolic Diseases and Comorbidities, Sorbonne Université, Inserm, Université de Paris, Paris, France.
- Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
- Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Université de Lorraine, INSERM Centre d'Investigations Cliniques-Plurithématique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT, Nancy, France.
ORCID-Profile: Roberto Palacios-Ramirez, Natalia Lopez-Andres, Frederic Jaisser
Förderung
- Agence Nationale de la Recherche (ANR)
- Institut National de la Santé et de la Recherche Médicale (Inserm)
Zitieren
APA
Palacios-Ramirez, R., Soulié, M., Fernandez-Celis, A., Nakamura, T., Boujardine, N., Bonnard, B., Bamberg, K., Lopez-Andres, N., & Jaisser, F. (2024). Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway. Clinical Science. https://doi.org/10.1042/cs20240302
Vancouver
Palacios-Ramirez R, Soulié M, Fernandez-Celis A, Nakamura T, Boujardine N, Bonnard B, et al. Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway. Clinical Science. 2024. doi:10.1042/cs20240302
BibTeX
@article{PalaciosRamirez2024,
author = {Palacios-Ramirez, Roberto and Soulié, Matthieu and Fernandez-Celis, Amaya and Nakamura, Toshifumi and Boujardine, Nabiha and Bonnard, Benjamin and Bamberg, Krister and Lopez-Andres, Natalia and Jaisser, Frederic},
title = {Mineralocorticoid receptor (MR) antagonist eplerenone and MR modulator balcinrenone prevent renal extracellular matrix remodeling and inflammation via the MR/proteoglycan/TLR4 pathway},
journal = {Clinical Science},
year = {2024},
doi = {10.1042/cs20240302}
}
EUVIMED